Evidence map›Paper›PMID 33213069›Full record

ArticleInternational journal of molecular sciences2020

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis.

Pol Andrés-Benito, Mònica Povedano, Raúl Domínguez, Carla Marco, Maria J Colomina, Óscar López-Pérez, Isabel Santana, Inês Baldeiras, Sergio Martínez-Yelámos, Inga Zerr and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.Journal of experimental & clinical cancer research : CR · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Pol Andrés-BenitoDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-3000-0338
Mònica PovedanoInternational Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.
Raúl DomínguezInternational Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.
Carla MarcoInternational Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.
Maria J ColominaAnesthesia and Critical Care Department, Bellvitge University Hospital-University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-0106-0956
Óscar López-PérezBiomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-2454-2114
Isabel SantanaNeurology Department, CHUC-Centro Hospitalar e Universitário de Coimbra, CNC-Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal.
Inês BaldeirasNeurology Department, CHUC-Centro Hospitalar e Universitário de Coimbra, CNC-Center for Neuroscience and Cell Biology; and Faculty of Medicine, University of Coimbra, 3000-456 Coimbra, Portugal.
Sergio Martínez-YelámosMultiple Sclerosis Unit, Service of Neurology, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Inga ZerrDepartment of Neurology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0002-6722-2463
Franc LlorensDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-9756-7497
Joaquín Fernández-IrigoyenIDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
Enrique SantamaríaIDISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.ORCID 0000-0001-8046-8102
Isidro FerrerDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-9888-8754
Bellvitge University Hospital · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESHospitais da Universidade de Coimbra · PTUniversidad Publica de Navarra · ESGerman Center for Neurodegenerative Diseases · DE

Funding

Institute Carlos III FISPI17/000809
6 · The paper itself

Abstract

Sporadic amyotrophic lateral sclerosis (sALS) is a fatal progressive neurodegenerative disease affecting upper and lower motor neurons. Biomarkers are useful to facilitate the diagnosis and/or prognosis of patients and to reveal possible mechanistic clues about the disease. This study aimed to identify and validate selected putative biomarkers in the cerebrospinal fluid (CSF) of sALS patients at early disease stages compared with age-matched controls and with other neurodegenerative diseases including Alzheimer disease (AD), spinal muscular atrophy type III (SMA), frontotemporal dementia behavioral variant (FTD), and multiple sclerosis (MS). SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for protein quantitation, and ELISA for validation, were used in CSF samples of sALS cases at early stages of the disease. Analysis of mRNA and protein expression was carried out in the anterior horn of the lumbar spinal cord in post-mortem tissue of sALS cases (terminal stage) and controls using RTq-PCR, and Western blotting, and immunohistochemistry, respectively. SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed 51 differentially expressed proteins in the CSF in sALS. Receiver operating characteristic (ROC) curves showed CXCL12 to be the most valuable candidate biomarker. We validated the values of CXCL12 in CSF with ELISA in two different cohorts. Besides sALS, increased CXCL12 levels were found in MS but were not altered in AD, SMA, and FTD. Therefore, increased CXCL12 levels in the CSF can be useful in the diagnoses of MS and sALS in the context of the clinical settings. CXCL12 immunoreactivity was localized in motor neurons in control and sALS, and in a few glial cells in sALS at the terminal stage; CXCR4 was in a subset of oligodendroglial-like cells and axonal ballooning of motor neurons in sALS; and CXCR7 in motor neurons in control and sALS, and reactive astrocytes in the pyramidal tracts in terminal sALS. CXCL12/CXCR4/CXCR7 axis in the spinal cord probably plays a complex role in inflammation, oligodendroglial and astrocyte signaling, and neuronal and axonal preservation in sALS.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyotrophic Lateral SclerosisBiomarkersChemokine CXCL12FemaleFrontotemporal DementiaHumansMaleMiddle AgedMotor NeuronsNeurogliaReceptors, CXCRReceptors, CXCR4ACKR3 protein, humanBiomarkersChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanReceptors, CXCRReceptors, CXCR4AAASamyotrophic lateral sclerosisbiomarkerscerebrospinal fluidCXCL12CXCR4CXCR7proteomicsS1006A

Identifiers

PMID33213069
PMCPMC7698527
OpenAlexW3099506149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.